Literature DB >> 20004475

Humoral immunity in tuberculin skin test anergy and its role in high-risk persons exposed to active tuberculosis.

Liliana Encinales1, Joaquin Zuñiga, Julio Granados-Montiel, Maria Yunis, Julio Granados, Ingrid Almeciga, Olga Clavijo, Carlos Awad, Vilma Collazos, María Inés Vargas-Rojas, José Luis Bañales-Mendez, Lilia Vazquez-Castañeda, Joel N Stern, Viviana Romero, Masha Fridkis-Hareli, Masha Frindkis-Hareli, Daniel Terreros, Marcelo Fernandez-Viña, Edmond J Yunis.   

Abstract

The most common test to identify latent tuberculosis is the tuberculin skin test that detects T cell responses of delayed type hypersensitivity type IV. Since it produces false negative reactions in active tuberculosis or in high-risk persons exposed to tuberculosis patients as shown in this report, we studied antibody profiles to explain the anergy of such responses in high-risk individuals without active infection. Our results showed that humoral immunity against tuberculin, regardless of the result of the tuberculin skin test is important for protection from active tuberculosis and that the presence of high antibody titers is a more reliable indicator of infection latency suggesting that latency can be based on the levels of antibodies together with in vitro proliferation of peripheral blood mononuclear cells in the presence of the purified protein derivative. Importantly, anti-tuberculin IgG antibody levels mediate the anergy described herein, which could also prevent reactivation of disease in high-risk individuals with high antibody titers. Such anti-tuberculin IgG antibodies were also found associated with blocking and/or stimulation of in vitro cultures of PBMC with tuberculin. In this regard, future studies need to establish if immune responses to Mycobacterium tuberculosis can generate a broad spectrum of reactions either toward Th1 responses favoring stimulation by cytokines or by antibodies and those toward diminished responses by Th2 cytokines or blocking by antibodies; possibly involving mechanisms of antibody dependent protection from Mtb by different subclasses of IgG. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20004475      PMCID: PMC2815102          DOI: 10.1016/j.molimm.2009.11.005

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  29 in total

1.  Tissue transplantation: a new approach to the "typing" problem.

Authors:  L BRENT; P B MEDAWAR
Journal:  Br Med J       Date:  1963-08-03

2.  A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival.

Authors:  R Teitelbaum; A Glatman-Freedman; B Chen; J B Robbins; E Unanue; A Casadevall; B R Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

Review 3.  Tuberculosis in patients with human immunodeficiency virus infection.

Authors:  D V Havlir; P F Barnes
Journal:  N Engl J Med       Date:  1999-02-04       Impact factor: 91.245

4.  Cross-reactivity and sequence homology between the 65-kilodalton mycobacterial heat shock protein and human lactoferrin, transferrin, and DR beta subsets of major histocompatibility complex class II molecules.

Authors:  A Aguas; N Esaguy; C E Sunkel; M T Silva
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

5.  Blocking of autologous and homologous leukocyte responses by human alloimmune plasmas: a possible in vitro correlate of enhancement.

Authors:  R H Buckley; R I Schiff; D B Amos
Journal:  J Immunol       Date:  1972-01       Impact factor: 5.422

6.  An epidemic of tuberculosis with a high rate of tuberculin anergy among a population previously unexposed to tuberculosis, the Yanomami Indians of the Brazilian Amazon.

Authors:  A O Sousa; J I Salem; F K Lee; M C Verçosa; P Cruaud; B R Bloom; P H Lagrange; H L David
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

7.  The Mycobacterium tuberculosis 19-kilodalton lipoprotein inhibits gamma interferon-regulated HLA-DR and Fc gamma R1 on human macrophages through Toll-like receptor 2.

Authors:  Adam J Gehring; Roxana E Rojas; David H Canaday; David L Lakey; Clifford V Harding; W Henry Boom
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

8.  DONOR SELECTION IN HUMAN ORGAN TRANSPLANTATION. A POSSIBLE SCREENING TEST.

Authors:  J G GRAY; P S RUSSELL
Journal:  Lancet       Date:  1963-10-26       Impact factor: 79.321

Review 9.  Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis.

Authors:  A Glatman-Freedman; A Casadevall
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

Review 10.  Molecular mimicry and immune-mediated diseases.

Authors:  M B Oldstone
Journal:  FASEB J       Date:  1998-10       Impact factor: 5.191

View more
  11 in total

1.  Effects of Serial Skin Testing with Purified Protein Derivative on the Level and Quality of Antibodies to Complex and Defined Antigens in Mycobacterium bovis-Infected Cattle.

Authors:  W Ray Waters; Mitchell V Palmer; Molly R Stafne; Kristin E Bass; Mayara F Maggioli; Tyler C Thacker; Rick Linscott; John C Lawrence; Jeffrey T Nelson; Javan Esfandiari; Rena Greenwald; Konstantin P Lyashchenko
Journal:  Clin Vaccine Immunol       Date:  2015-04-08

Review 2.  B cells and antibodies in the defense against Mycobacterium tuberculosis infection.

Authors:  Jacqueline M Achkar; John Chan; Arturo Casadevall
Journal:  Immunol Rev       Date:  2015-03       Impact factor: 12.988

Review 3.  Antibody-mediated immunity against tuberculosis: implications for vaccine development.

Authors:  Jacqueline M Achkar; Arturo Casadevall
Journal:  Cell Host Microbe       Date:  2013-03-13       Impact factor: 21.023

Review 4.  Role of B cells and antibodies in acquired immunity against Mycobacterium tuberculosis.

Authors:  Jacqueline M Achkar; John Chan; Arturo Casadevall
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-09       Impact factor: 6.915

Review 5.  Cellular and humoral mechanisms involved in the control of tuberculosis.

Authors:  Joaquin Zuñiga; Diana Torres-García; Teresa Santos-Mendoza; Tatiana S Rodriguez-Reyna; Julio Granados; Edmond J Yunis
Journal:  Clin Dev Immunol       Date:  2012-05-17

6.  A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.

Authors:  Alice Minhinnick; Iman Satti; Stephanie Harris; Morven Wilkie; Sharon Sheehan; Lisa Stockdale; Zita-Rose Manjaly Thomas; Raquel Lopez-Ramon; Ian Poulton; Alison Lawrie; Samantha Vermaak; Alexandre Le Vert; Judith Del Campo; Fergal Hill; Paul Moss; Helen McShane
Journal:  Vaccine       Date:  2016-02-05       Impact factor: 3.641

Review 7.  Antibodies and tuberculosis.

Authors:  Ashley J Jacobs; Juthathip Mongkolsapaya; Gavin R Screaton; Helen McShane; Robert J Wilkinson
Journal:  Tuberculosis (Edinb)       Date:  2016-08-26       Impact factor: 3.131

Review 8.  Host-Directed Therapeutic Strategies for Tuberculosis.

Authors:  Afsal Kolloli; Selvakumar Subbian
Journal:  Front Med (Lausanne)       Date:  2017-10-18

9.  Comparison between the Interferon γ Release Assay-QuantiFERON Gold Plus (QFT-Plus)-and Tuberculin Skin Test (TST) in the Detection of Tuberculosis Infection in Immunocompromised Children.

Authors:  Cory Primaturia; Lelani Reniarti; Heda M N Nataprawira
Journal:  Pulm Med       Date:  2020-05-10

10.  A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.

Authors:  Sharon Sheehan; Stephanie A Harris; Iman Satti; David A Hokey; Veerabadran Dheenadhayalan; Lisa Stockdale; Zita-Rose Manjaly Thomas; Alice Minhinnick; Morven Wilkie; Samantha Vermaak; Joel Meyer; Matthew K O'Shea; Maria Grazia Pau; Isabella Versteege; Macaya Douoguih; Jenny Hendriks; Jerald Sadoff; Bernard Landry; Paul Moss; Helen McShane
Journal:  PLoS One       Date:  2015-11-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.